Delving into the Latest Updates on Certoparin sodium with Synapse

The management of pregnant women at increased risk of thromboembolic/other vascular events is still a matter of debate. In a single-center, retrospective, observational trial, we analyzed the safety and efficacy of prophylactic anticoagulation with certoparin in pregnant women at intermediate- or high-risk by EThIG criteria of thromboembolic/other vascular events. Subcutaneous certoparin 8,000 IU once daily was administered immediately after pregnancy confirmation and continued for 6 weeks postpartum. We investigated 74 pregnancies (49 women; mean age 31.8 years; weight 77.3 kg). Most prevalent risk factors were factor V Leiden mutation (40.5%), thrombogenic factor II mutation (12.2%) and protein S deficiency (8.1%). In 76 control pregnancies prior to registry inclusion/without anticoagulation there were 14 cases [18.4%] of venous thromboembolism (between week 7 gestation and week 8 postpartum); 63.2% pregnancies resulted in abortion (median week 8.6 gestation). With certoparin anticoagulation, thromboembolism was 1.4%, exclusively non-major bleeding was 4.1% and abortion was 10.8%. One case of pre-eclampsia necessitating obstetric intervention occurred. Prophylactic anticoagulation with intermediate-dose certoparin throughout pregnancies at increased venous vascular risk was safe and effective.

01 Nov 2020·DMW - Deutsche Medizinische WochenschriftQ4 · MEDICINE

Plötzliche Belastungsdyspnoe bei einer jungen Frau – internistisch-gynäkologisches Grenzgebiet in der Notaufnahme

Q4 · MEDICINE

Article

Author: Lock, Guntram ; Mehl, Lisa ; Donner, Johanna

01 Jan 2019·Progress in Molecular Biology and Translational ScienceQ3 · BIOLOGY

Low molecular weight heparins and their clinical applications

Q3 · BIOLOGY

Review

Author: Hao, Cui ; Wang, Wei ; Sun, Mojian ; Wang, Hongmei ; Zhang, Lijuan

Heparin is an anticoagulant medication that was discovered in 1917 and used in clinic since 1935. Low molecular weight heparins (LMWHs) represent a refined use of heparin as anticoagulant medications that were developed in 1980s. LMWHs are obtained by cleaving heparin with different chemical or enzymatic methods. Eight chemically distinct and officially approved LMWHs are Bemiparin, Certoparin, Dalteparin, Enoxaparin, Nadroparin, Parnaparin, Reviparin, and Tinzaparin. LMWHs are mainly used for preventing blood clots, for treating deep vein thrombosis and pulmonary embolism, and for treating myocardial infarction. LMWHs have advantages over heparin in that they can be used at home with good predictability, dose-dependent plasma levels, a long half-life, less bleeding for a given antithrombotic even, smaller risk of osteoporosis in long-term use, and smaller risk of heparin-induced thrombocytopenia and thrombosis, a potential side effect of heparin. However, heparin is reversible with protamine sulfate while LMWHs have no antidote. Moreover, LMWHs have less of an effect on inhibiting thrombin activity than heparin. Furthermore, patients with end-stage renal diseases have to use heparin because LMWHs are dependent on functioning kidney for their clearance but heparin is primarily cleared in the liver. We will review the recent progress made on the clinically approved and under clinical trialed LMWHs and their potential medical applications. In particular, we will provide an update on the chemical characteristics and clinical use of different branded LMWHs. In addition, the potential clinical applications of LMWHs in other therapeutic area will also be discussed.

100 Deals associated with Certoparin sodium

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	Certoparin sodium	B01AB	DB09261

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Pulmonary Embolism	-	-	01 Jan 1997
Thromboembolism	-	-	01 Jan 1997
Venous Thrombosis	-	-	01 Jan 1997

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Renal Insufficiency	Discovery	HU	Novartis Pharmaceuticals Corp.	01 Dec 2011
Kidney Failure, Chronic	Discovery	DE	Novartis Pharma AG	01 Nov 2010
Uremia	Discovery	DE	Novartis Pharma AG	01 Nov 2010
Thromboembolism	Discovery	DE	Novartis AG	01 Jan 2007
Embolism	Discovery	DE	Novartis Pharma AG	01 Feb 2006
Embolism	Discovery	CH	Novartis Pharma AG	01 Feb 2006
Atrial Fibrillation	Discovery	US	Novartis AG	01 Apr 2005
Atrial Fibrillation	Discovery	DE	Novartis AG	01 Apr 2005

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01179620 (Pubmed \| BMC Nephrol)	Phase 3	Maintenance	109	Certoparin	gftprxzrzu(cwbxkypwkf) = hpjnopzlgk kvnkrkpnoj (mefgmczoqg, 3.00 - 4.45) View more	Positive	28 Jun 2012
NCT00311753 (CERTAIN, Pubmed \| Expert Opin Pharmacother)	Phase 3	-	342	Certoparin 3000 IU daily	(zxzxyulouo) = Major bleeding events occurred in three patients with UFH and one patient with certoparin etijtpgfaq (ebjdrgoolm )	Positive	01 Dec 2010
NCT00311753 (CERTAIN, Pubmed \| Expert Opin Pharmacother)	Phase 3	-	342	UFH 7500 IU twice daily		Positive	01 Dec 2010
NCT00171769 (Pubmed \| Clin Res Cardiol)	Phase 3	Atrial Fibrillation	203	Certoparin 8000 U anti-Xa	(xqjeofrcyj) = wjutuzupod yuzbajmgzi (myrwctoxwf ) View more	-	01 Jun 2008